Uncommon single and compound EGFR mutations: Clinical outcomes of a heterogeneous subgroup of NSCLC
S Rossi, P Damiano, L Toschi, G Finocchiaro… - Current Problems in …, 2022 - Elsevier
Molecular characterization of non-small-cell lung cancer (NSCLC) is essential to define the
correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth …
correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth …
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC
S Rossi, P Damiano, L Toschi… - Current problems …, 2022 - pubmed.ncbi.nlm.nih.gov
Molecular characterization of non-small-cell lung cancer (NSCLC) is essential to define the
correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth …
correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth …
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.
S Rossi, P Damiano, L Toschi… - Current Problems in …, 2021 - europepmc.org
Molecular characterization of non-small-cell lung cancer (NSCLC) is essential to define the
correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth …
correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth …
[引用][C] Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC
S Rossi, P Damiano, L Toschi… - CURRENT …, 2021 - iris.hunimed.eu
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous
subgroup of NSCLC IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste IT …
subgroup of NSCLC IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste IT …